ALK and non-small cell lung carcinoma: In a previous publication [26], we could retrospectively validate a multiplexed RNA-based nCounter codeset for the detection of ALK, ROS1, and RET fusion transcripts in FFPE samples from patients with advanced NSCLC, proving its advantage compared to standard diagnostic assays, such as fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC).